Health
Vaccine Partners Turn Rivals With First Shot for Advancing Virus
- Valneva, Bavarian will compete to sell their chikungunya shots
- Firms compete for a market estimated to exceed $500 million
This article is for subscribers only.
Two European partners will soon be vying for dominance in a new battleground: vaccines to protect travelers against a painful viral illness transmitted by mosquitoes.
Valneva SE became the first company to win clearance late last year to sell a shot for chikungunya, a disease that can cause fever and severe joint pain. Bavarian Nordic A/S is some months behind, awaiting approval in the European Union and starting a submission in the US.